Drug Profile
Research programme: anti-interleukin 23 monoclonal antibody - Femta
Alternative Names: FM303Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Femta Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammatory-bowel-disease in USA (Parenteral)